tradmap

SEER Seer, Inc.

$1.75 +3.86%

Data as of close

Healthcare · Laboratory Analytical Instruments

Seer, Inc. (SEER) is a healthcare company in the Laboratory Analytical Instruments industry, with a market capitalization of $97 million. Shares last traded at $1.75, 26.0% below their 52-week high. Over the past year the stock is down 21.5%. Net profit margin is -478.0%, below the peer median of 1.9%. Revenue grew 17.0% year over year.

Market Cap
$97M
Shares Out
55.4M
EPS (TTM)
—
P/E (TTM)*
—
P/S Ratio
6.82
P/B Ratio
0.43
Dividend / Share
—
Dividend Yield
—
52-Week High
$2.37
52-Week Low
$1.55
Volume (venue)
28,289
Avg Vol (3m, venue)
17,190.27

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-9.56%
1M
-22.22%
3M
-20.99%
6M
-10.49%
YTD
-4.11%
1Y
-21.52%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
33.71
SMA (50)
$2.00
SMA (200)
$1.92
Price vs SMA50
-12.63%
Price vs SMA200
-9.07%
ATR (14)
$0.09

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$14M
Net Income
-$68M
Gross Margin
47.7%
Operating Margin
-498.2%
Net Margin
-478.0%
Return on Equity
-30.1%
Return on Assets
-26.5%
Current Ratio
14.74
Debt / Equity
0.14
Revenue Growth (YoY)
+17.0%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2024 -$0.35 2024-11-06
Q2 2024 -$0.35 2024-08-08
Q1 2024 -$0.32 2024-05-08
Q4 2023 (derived) -$0.27 2024-03-04
FY 2023 -$1.35 2024-03-04
Q3 2023 -$0.33 2023-11-07

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Laboratory Analytical Instruments peers

SEER vs 14 industry peers (Laboratory Analytical Instruments), by market cap. Data as of close

P/S vs peers
6.82 / 4.80 med
+42% premium
Net margin vs peers
-478.0% / 1.9% med
below median
1–14 of 14
AAgilent Technologies$48.5B33.686.5819.5%-1.62%
WATWaters Corporation$44.2B68.719.5113.8%-2.86%
ILMNIllumina, Inc.$34.2B38.267.5519.7%-4.10%
MTDMettler Toledo$33.6B37.148.1421.9%+0.17%
RVTYRevvity$16.9B71.265.818.2%-3.38%
AVTRAvantor, Inc.$10.6B31.351.595.1%-2.86%
BIOBio-Rad Laboratories, Inc.$9.8B44.033.788.6%-1.57%
BRKRBruker Corp$8.5B—2.42-2.0%-2.48%
TXG10x Genomics, Inc.$8.0B—13.01-12.2%-12.14%
ALMRAlamar Biosciences, Inc.$2.0B———-5.48%
CTKBCytek Biosciences, Inc.$751M—3.63-32.2%-5.56%
PACBPacific Biosciences Of California, Inc.$727M———-10.34%
MASS908 Devices Inc.$421M—6.92-57.0%-9.26%
NAUTNautilus Biotechnology, Inc.$302M———-13.50%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.